Literature DB >> 10817245

Radioimmunoassay for the measurement of thrombospondin in plasma and breast cyst fluid: validation and clinical application.

K Hayden1, L Tetlow, G Byrne, N Bundred.   

Abstract

Thrombospondin is an adhesive protein that has been implicated in malignancy, specifically in tumour progression and angiogenesis. We developed a radioimmunoassay for the measurement of thrombospondin in plasma and breast cyst fluid. The assay exhibited high accuracy, with recoveries of 102-136% and acceptable imprecision, with an intra-assay coefficient of variation (CV) of <7.5% across the analytical range 30-1000 ng/mL and inter-assay CV of 4.4% and 7.7% at 152 and 224 ng/mL, respectively. Thrombospondin measured in the breast cyst fluid of patients with gross cystic disease of the breast showed that patients with type II (Na+) cysts had significantly higher concentrations than type I (K+) cysts. The plasma thrombospondin reference range was determined as 131-274 ng/mL. Patients with breast cancer had significantly higher plasma thrombospondin concentrations than normal individuals or patients with benign breast disease. Plasma thrombospondin was higher in breast cancer patients with lymph node involvement.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10817245     DOI: 10.1258/0004563001899212

Source DB:  PubMed          Journal:  Ann Clin Biochem        ISSN: 0004-5632            Impact factor:   2.057


  5 in total

Review 1.  Candidate-based proteomics in the search for biomarkers of cardiovascular disease.

Authors:  Leigh Anderson
Journal:  J Physiol       Date:  2004-12-20       Impact factor: 5.182

2.  Inhibition of proliferation and migration of luminal and claudin-low breast cancer cells by PDGFR inhibitors.

Authors:  Leanne Stalker; James Pemberton; Roger A Moorehead
Journal:  Cancer Cell Int       Date:  2014-09-05       Impact factor: 5.722

Review 3.  Human expression patterns: qualitative and quantitative analysis of thrombospondin-1 under physiological and pathological conditions.

Authors:  Chen Zhao; Jeffrey S Isenberg; Aleksander S Popel
Journal:  J Cell Mol Med       Date:  2018-02-14       Impact factor: 5.310

4.  A list of candidate cancer biomarkers for targeted proteomics.

Authors:  Malu Polanski; N Leigh Anderson
Journal:  Biomark Insights       Date:  2007-02-07

5.  Thrombospondin-1 Silencing Down-Regulates Integrin Expression Levels in Human Anaplastic Thyroid Cancer Cells with BRAF(V600E): New Insights in the Host Tissue Adaptation and Homeostasis of Tumor Microenvironment.

Authors:  Mark Duquette; Peter M Sadow; Jack Lawler; Carmelo Nucera
Journal:  Front Endocrinol (Lausanne)       Date:  2013-12-02       Impact factor: 5.555

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.